T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HOLX
226
DELISTED
Hologic
HOLX
| $507M | 0.1% |
13,330,100
+4,440,820
| +50% | +$155M |
|
227
News Corp Class A
NWSA
$15.5B
| $503M | 0.1% |
34,489,226
+6,688,420
| +24% | +$103M |
|
228
Verisk Analytics
VRSK
$23.6B
| $494M | 0.1% |
6,794,091
-2,554,615
| -27% | -$188M |
|
|
WUBA
229
DELISTED
58.com Inc
WUBA
| $489M | 0.1% |
7,632,959
+2,866,024
| +60% | +$208M |
|
230
Universal Health Services
UHS
$9.94B
| $487M | 0.1% |
3,427,973
-1,675,750
| -33% | -$210M |
|
|
VIAB
231
DELISTED
Viacom Inc. Class B
VIAB
| $482M | 0.1% |
7,459,164
-688,704
| -8% | -$46.6M |
|
232
Coca-Cola
KO
$372B
| $481M | 0.1% |
12,253,829
-162,528
| -1% | -$6.61M |
|
233
Choice Hotels
CHH
$4.62B
| $480M | 0.1% |
8,855,112
+225,649
| +3% | +$13.2M |
|
234
Nucor
NUE
$61.9B
| $480M | 0.1% |
10,887,034
+1,297,030
| +14% | +$62.2M |
|
235
L3Harris
LHX
$53.3B
| $477M | 0.1% |
6,205,485
-222,080
| -3% | -$17.6M |
|
|
WP
236
DELISTED
Worldpay, Inc.
WP
| $472M | 0.1% |
12,361,478
-6,367,693
| -34% | -$253M |
|
237
Neurocrine Biosciences
NBIX
$16.5B
| $468M | 0.1% |
9,793,739
-84,100
| -0.9% | -$3.57M |
|
|
238
Wynn Resorts
WYNN
$10.8B
| $464M | 0.1% |
4,703,581
-9,873,220
| -68% | -$1.11B |
|
239
Marriott International
MAR
$91.1B
| $463M | 0.1% |
6,224,459
-119,586
| -2% | -$9.45M |
|
240
Conagra Brands
CAG
$7.14B
| $462M | 0.1% |
13,570,790
-131,043
| -1% | -$3.93M |
|
|
CLGX
241
DELISTED
Corelogic, Inc.
CLGX
| $455M | 0.09% |
11,461,661
-1,255,835
| -10% | -$47.9M |
|
242
Illumina
ILMN
$29.1B
| $452M | 0.09% |
2,130,213
-127,202
| -6% | -$24.8M |
|
243
General Motors
GM
$78.4B
| $451M | 0.09% |
13,543,438
-557,420
| -4% | -$19.9M |
|
244
Trimble
TRMB
$13.5B
| $446M | 0.09% |
19,018,014
+4,516,907
| +31% | +$110M |
|
245
Teva Pharmaceuticals
TEVA
$42.5B
| $445M | 0.09% |
7,526,464
+114,904
| +2% | +$7.09M |
|
246
Aptiv
APTV
$10.3B
| $440M | 0.09% |
5,168,931
-2,864,090
| -36% | -$245M |
|
247
Deere & Co
DE
$167B
| $438M | 0.09% |
4,516,586
+9,380
| +0.2% | +$853K |
|
|
CVC
248
DELISTED
CABLEVISION SYS CP NY GRP CL-A
CVC
| $438M | 0.09% |
18,288,657
-3,898,180
| -18% | -$84.6M |
|
249
Altria Group
MO
$109B
| $430M | 0.09% |
8,800,924
+3,259,382
| +59% | +$165M |
|
250
Clorox
CLX
$13.1B
| $430M | 0.09% |
4,129,970
-17,410
| -0.4% | -$1.88M |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.